4-(Difluoromethyl)-5-(4-((3R,5S)-3,5-dimethylmorpholino)-6-((R)-3-methylmorpholino)-1,3,5-triazin-2-yl)pyridin-2-amine (PQR626), a Potent, Orally Available, and Brain-Penetrant mTOR Inhibitor for the Treatment of Neurological Disorders-Reference-Cited by-同舟云学术

4-(Difluoromethyl)-5-(4-((3R,5S)-3,5-dimethylmorpholino)-6-((R)-3-methylmorpholino)-1,3,5-triazin-2-yl)pyridin-2-amine (PQR626), a Potent, Orally Available, and Brain-Penetrant mTOR Inhibitor for the Treatment of Neurological Disorders

Published:2020-11-09 Issue:22 Volume:63 Page:13595-13617
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Borsari Chiara¹^ORCID,Keles Erhan¹,Rageot Denise¹,Treyer Andrea²^ORCID,Bohnacker Thomas¹,Bissegger Lukas¹,De Pascale Martina¹,Melone Anna¹,Sriramaratnam Rohitha¹,Beaufils Florent³,Hamburger Matthias²^ORCID,Hebeisen Paul³,Löscher Wolfgang⁴⁵,Fabbro Doriano³,Hillmann Petra³,Wymann Matthias P.¹^ORCID

Affiliation:

1. Department of Biomedicine, University of Basel, Mattenstrasse 28, 4058 Basel, Switzerland

2. Pharmaceutical Biology, Pharmacenter, University of Basel, Klingelbergstrasse 50, 4056 Basel, Switzerland

3. PIQUR Therapeutics AG, Hochbergerstrasse 60, 4057 Basel, Switzerland

4. Department of Pharmacology, Toxicology and Pharmacy, University of Veterinary Medicine, 30559 Hannover, Germany

5. Center for Systems Neuroscience, University of Veterinary Medicine, 30559 Hannover, Germany

Funder

Schweizerischer Nationalfonds zur F?rderung der Wissenschaftlichen Forschung

Epilepsy Foundation

Kommission f?r Technologie und Innovation

Novartis Stiftung?f?r?Medizinisch-Biologische Forschung

Innosuisse - Schweizerische Agentur f?r Innovationsf?rderung